Tech Company Financing Transactions
Envisagenics Funding Round
On 6/5/2024, Envisagenics received Series B financing from Bristol Myers Squibb, Empire State Development and Red Cell Partners.
Transaction Overview
Company Name
Announced On
6/5/2024
Transaction Type
Venture Equity
Amount
Unknown
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to further develop its pipeline of novel preclinical oncology assets with its cloud-based AI drug discovery platform, SpliceCore®, and to scale its commercial offerings.
Company Information
Company Status
Private & Independent
Industry
Healthcare IT
Mailing Address
101 Ave. of the Americas 3rd Floor
New York, NY 10013
USA
New York, NY 10013
USA
Phone
Website
Email Address
Overview
Envisagenics is a New York City-based a bioinformatics company. Biomedical data might hold the key to finding the cure for currently incurable diseases. Our mission is to reduce the complexity of RNA-seq data into plausible candidates for drug and biomarker development.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Maria Pineda
Chief Technical Officer
Martin Akerman
Browse more venture capital transactions:
Prev: 6/5/2024: Fispoke venture capital transaction
Next: 6/5/2024: Liminal venture capital transaction
Share this article
News on VC Transactions
We do our best to record every notable VC transaction. VC transactions on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs